---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-000999"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T03:56:28.430338+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relmada provides 2024 outlook: REL-1017 study 302 ~50% enrolled; psilocybin Phase 1 planned

## Summary
- REL-1017 Phase 3 study 302 (Reliance II) is approximately 50% enrolled (target ~300 patients); full enrollment expected H1 2024.
- REL-1017 Phase 3 study 304 (Relight) enrollment to complete by year-end 2024, also ~300 patients.
- Phase 1 trial of modified-release psilocybin (REL-P11) in obese patients with steatotic liver disease to start H1 2024; Phase 2a data expected H1 2025.
- Dr. Cedric O'Gorman steps down as CMO; Dr. Andrew Cutler appointed Senior Clinical Development Advisor to support NDA process.
- Cash runway expected to extend beyond all 2024 catalysts; no specific cash balance disclosed.

## SEC filing metadata
- accession: 0001213900-24-000999
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390024000999/0001213900-24-000999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390024000999/ea191114-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-000999
- JSON: https://secwatch.observer/filing/0001213900-24-000999.json
- Plain text: https://secwatch.observer/filing/0001213900-24-000999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.